Characteristics and predictors of drug-eluting stent thrombosis: results from the multicenter 'Korea Stent Thrombosis (KoST)' registry.

BACKGROUND Previous studies have reported possible predictors of drug-eluting stent thrombosis (ST), but data for Asians are relatively limited. This study was performed to elucidate clinical predictors of ST in Koreans. METHODS AND RESULTS From May 2003 to May 2007, consecutive patients presenting with ST were enrolled from 10 cardiovascular centers in Korea. They were compared with 2,192 controls (3,223 lesions) who had received percutaneous coronary intervention with at least 6 months of follow-up without ST. On multivariate analysis, acute myocardial infarction (AMI) as initial diagnosis, drug-eluting stents (DES) in-stent restenosis (ISR), low ejection fraction (EF), small stent diameter, left anterior descending artery intervention, and young age were independent predictors of total ST. When divided into early (ST within 30 days of index procedure) and delayed ST (ST after 30 days of index procedure), low EF, small stent diameter, DES ISR and AMI as initial diagnosis were universal risks for both early and delayed ST. The time from antiplatelet agent discontinuation to ST occurrence was significantly shorter in late compared with very late ST. CONCLUSIONS Predictors of ST may be slightly different for early vs. delayed ST. However, low EF, small stent diameter, DES ISR lesion, and AMI as initial diagnosis were universal risk factors for both early and delayed ST cases. The relationship between antiplatelet agent discontinuation and ST occurrence seems stronger in late compared with very late ST.

[1]  D. Kereiakes.  Safety of drug-eluting stents. , 2010, Reviews in cardiovascular medicine.

[2]  T. Kume,et al.  Comparisons of Baseline Demographics, Clinical Presentation, and Long-Term Outcome Among Patients With Early, Late, and Very Late Stent Thrombosis of Sirolimus-Eluting Stents: Observations From the Registry of Stent Thrombosis for Review and Reevaluation (RESTART) , 2010, Circulation.

[3]  L. Thuesen,et al.  Late coronary stent thrombosis. , 2010, Minerva medica.

[4]  B. Yoo,et al.  The Significance of Clopidogrel Low-Responsiveness on Stent Thrombosis and Cardiac Death Assessed by the Verifynow P2Y12 Assay in Patients With Acute Coronary Syndrome Within 6 Months After Drug-Eluting Stent Implantation , 2009, Korean circulation journal.

[5]  Yoshinobu Morikawa,et al.  Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[6]  R. Starzyk,et al.  Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. , 2009, Circulation. Cardiovascular interventions.

[7]  K. Hirata,et al.  Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow up by optical coherence tomography. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[8]  K. Filion,et al.  Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents , 2009, Circulation.

[9]  Y. Hayashi,et al.  Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation , 2009, Circulation.

[10]  M. Jeong,et al.  A Fatal Case of Simultaneous, Very Late Thrombosis Involving Three Drug-Eluting Stents in Three Coronary Arteries , 2008 .

[11]  A. Gori,et al.  Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. , 2008, Journal of the American College of Cardiology.

[12]  Josepa Mauri,et al.  Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). , 2008, Journal of the American College of Cardiology.

[13]  R. Waksman,et al.  Drug-eluting stent safety. , 2007, The American journal of cardiology.

[14]  E. Camenzind,et al.  Response to Letter Regarding Article, “Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern” , 2007 .

[15]  A. Colombo,et al.  Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment , 2007, Circulation.

[16]  A. Gori,et al.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.

[17]  Rolf Vogel,et al.  Incomplete Stent Apposition and Very Late Stent Thrombosis After Drug-Eluting Stent Implantation , 2007, Circulation.

[18]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[19]  G. Stone,et al.  Clinical ResearchInterventional CardiologyIncidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent: A TAXUS II, IV, V, and VI Meta-Analysis of 3,445 Patients Followed for Up to 3 Years , 2007 .

[20]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[21]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[22]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[23]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[24]  Seung‐Jung Park,et al.  Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. , 2006, The American journal of cardiology.

[25]  K. Kent,et al.  Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents , 2006, Circulation.

[26]  A. Hedger,et al.  Cause for concern , 2005, British Dental Journal.

[27]  Deepak L. Bhatt,et al.  Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). , 2005, The American journal of cardiology.

[28]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[29]  P. Serruys,et al.  Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. , 2005, Journal of the American College of Cardiology.

[30]  Deepak L. Bhatt,et al.  What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. , 2005, Journal of the American College of Cardiology.

[31]  Fernando Alfonso,et al.  Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. , 2005, Journal of the American College of Cardiology.

[32]  David J Cohen,et al.  Stent Thrombosis After Successful Sirolimus-Eluting Stent Implantation , 2004, Circulation.

[33]  D. Baim,et al.  Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials , 2001, Circulation.

[34]  M. Gawaz,et al.  Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. , 2010, European heart journal.